Pangenomic Health Inc. NARA
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -75.98% | -57.56% | -35.47% | 181.67% | 105.92% |
| Gross Profit | 75.98% | 57.56% | 35.47% | -181.67% | -105.92% |
| SG&A Expenses | 399.03% | 447.41% | 415.58% | 158.36% | -20.89% |
| Depreciation & Amortization | -77.78% | -90.00% | -93.55% | -95.24% | -80.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 158.18% | 183.21% | 182.48% | 157.40% | 12.65% |
| Operating Income | -158.18% | -183.21% | -182.48% | -157.40% | -12.65% |
| Income Before Tax | -133.85% | 0.66% | 10.77% | 4.73% | 51.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -133.85% | 0.66% | 10.77% | 4.73% | 51.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -133.85% | 0.66% | 10.77% | 4.73% | 51.75% |
| EBIT | -158.18% | -183.21% | -182.48% | -157.40% | -12.65% |
| EBITDA | -158.60% | -184.41% | -184.65% | -160.06% | -13.57% |
| EPS Basic | 21.64% | 69.65% | 69.57% | 59.74% | 74.39% |
| Normalized Basic EPS | 3.85% | 10.72% | 21.37% | 34.63% | 65.65% |
| EPS Diluted | 21.64% | 69.65% | 69.57% | 59.74% | 74.39% |
| Normalized Diluted EPS | 3.85% | 10.72% | 21.37% | 34.63% | 65.65% |
| Average Basic Shares Outstanding | 181.07% | 228.92% | 221.31% | 160.91% | 180.82% |
| Average Diluted Shares Outstanding | 181.07% | 228.92% | 221.31% | 160.91% | 180.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |